*Momo Morikawa1,2, Ashwaq Hassan Alsabban2,5, Yosuke Tanaka3, Yosuke Takei2,4, Nobutaka Hirokawa2,6 (1. Lab. for Mol. Psychiatry, RIKEN CBS, 2. Lab Mol Struct and Dynam, Univ of Tokyo, Tokyo, Japan, 3. Lab Struct Cell Biol, Univ of Tokyo, Tokyo, Japan, 4. Dept Anat and Neurosci, Univ of Tsukuba, Ibaraki, Japan, 5. Dept Biol Sci, King Abdulaziz Univ, Jeddah, Saudi Arabia, 6. CEGMR, King Abdulaziz Univ, Jeddah, Saudi Arabia)
Session information
Oral
[2O10m-2] Schizophrenia
Thu. Jul 30, 2020 10:00 AM - 11:00 AM Room 10
*Videos are available throughout the meeting period.
*KEIKO IKEMOTO1 (1. Dept Psychiatry, Iwaki City Medical Center)
*Fumito Sano1, Wataru Arihisa1, Tomoaki Kahyou1, Junya Matsumoto2, Sumio Ohtsuki3, Shuji Shigenobu4, Hidenori Yamasue5, Mitsutoshi Setou1 (1. Department of Cellular & Molecular Anatomy, Hamamatsu University School of Medicine, Shizuoka, Japan, 2. Department of Pathology of Mental Diseases, National Instituteof Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan, 3. Laboratory of Pharmaceutical Microbiology, Faculty of Life Science Kumamoto University, Kumamoto, Japan, 4. National Institute for Basic Biology, Functional Genomics Facility, Tokyo, Japan, 5. Department of Psychiatry, Hamamatsu University School of Medicine, Shizuoka, Japan)
*Miki Bundo1, Junko Ueda2, Emi Kiyota1, Kiyoto Kasai3, Tadafumi Kato2, Kazuya Iwamoto1 (1. Dept Molecular Brain Science, Kumamoto Univ, Kumamoto, Japan, 2. Lab for Molecular Dynamics of Mental Disorders, RIKEN CBS, Saitama, Japan, 3. Dept Neuropsychiatry, Univ of Tokyo, Tokyo, Japan)